

# Francesca Fanelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6042313/publications.pdf>

Version: 2024-02-01

152  
papers

6,834  
citations

71102

41  
h-index

74163

75  
g-index

157  
all docs

157  
docs citations

157  
times ranked

5874  
citing authors

#	ARTICLE	IF	CITATIONS
1	PSNtools for standalone and web-based structure network analyses of conformational ensembles. Computational and Structural Biotechnology Journal, 2022, 20, 640-649.	4.1	17
2	Frontiers in Multiscale Modeling of Photoreceptor Proteins. Photochemistry and Photobiology, 2021, 97, 243-269.	2.5	26
3	Structural aspects of rod opsin and their implication in genetic diseases. Pflugers Archiv European Journal of Physiology, 2021, 473, 1339-1359.	2.8	9
4	Structure network-based landscape of rhodopsin misfolding by mutations and algorithmic prediction of small chaperone action. Computational and Structural Biotechnology Journal, 2021, 19, 6020-6038.	4.1	4
5	ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. Nature Communications, 2020, 11, 5938.	12.8	22
6	Dynamics and structural communication in the ternary complex of fully phosphorylated V2 vasopressin receptor, vasopressin, and $\beta^2$ -arrestin 1. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183355.	2.6	6
7	webPSN v2.0: a webserver to infer fingerprints of structural communication in biomacromolecules. Nucleic Acids Research, 2020, 48, W94-W103.	14.5	56
8	Integrated structural modeling and super-resolution imaging resolve GPCR oligomers. Progress in Molecular Biology and Translational Science, 2020, 169, 151-179.	1.7	5
9	Membrane Estrogen Receptor (GPER) and Follicle-Stimulating Hormone Receptor (FSHR) Heteromeric Complexes Promote Human Ovarian Follicle Survival. IScience, 2020, 23, 101812.	4.1	29
10	ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine. Blood, 2020, 136, LBA-5-LBA-5.	1.4	1
11	Interconnecting Flexibility, Structural Communication, and Function in RhoGEF Oncoproteins. Journal of Chemical Information and Modeling, 2019, 59, 4300-4313.	5.4	13
12	Frontal Variant of Alzheimer's Disease: A Report of a Novel PSEN1 Mutation. Journal of Alzheimer's Disease, 2019, 70, 11-15.	2.6	8
13	Auto-regulation of Secretory Flux by Sensing and Responding to the Folded Cargo Protein Load in the Endoplasmic Reticulum. Cell, 2019, 176, 1461-1476.e23.	28.9	65
14	<i>ARM</i> : Automatic Rhodopsin Modeling with Chromophore Cavity Generation, Ionization State Selection, and External Counterion Placement. Journal of Chemical Theory and Computation, 2019, 15, 3134-3152.	5.3	44
15	Computational modeling approaches to quantitative structure-binding kinetics relationships in drug discovery. Drug Discovery Today, 2018, 23, 1396-1406.	6.4	20
16	A Small Chaperone Improves Folding and Routing of Rhodopsin Mutants Linked to Inherited Blindness. IScience, 2018, 4, 1-19.	4.1	50
17	Structural Determinants of Constitutive Activation of G $\alpha$ Proteins: Transducin as a Paradigm. Journal of Chemical Theory and Computation, 2017, 13, 886-899.	5.3	10
18	Epilepsy and intellectual disability linked protein Shrm4 interaction with GABABRs shapes inhibitory neurotransmission. Nature Communications, 2017, 8, 14536.	12.8	31

#	ARTICLE	IF	CITATIONS
19	Dissecting intrinsic and ligand-induced structural communication in the $\beta 3$ headpiece of integrins. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 2367-2381.	2.4	13
20	Class A GPCR: Di/Oligomerization of Glycoprotein Hormone Receptors. , 2017, , 207-231.		2
21	Modulation of thermal noise and spectral sensitivity in Lake Baikal cottoid fish rhodopsins. <i>Scientific Reports</i> , 2016, 6, 38425.	3.3	26
22	Small-Molecule Protein-Protein Interaction Inhibitor of Oncogenic Rho Signaling. <i>Cell Chemical Biology</i> , 2016, 23, 1135-1146.	5.2	28
23	Structure network analysis to gain insights into GPCR function. <i>Biochemical Society Transactions</i> , 2016, 44, 613-618.	3.4	21
24	WebPSN: a web server for high-throughput investigation of structural communication in biomacromolecules. <i>Bioinformatics</i> , 2015, 31, 779-781.	4.1	49
25	Single Molecule Analysis of Functionally Asymmetric G Protein-coupled Receptor (GPCR) Oligomers Reveals Diverse Spatial and Structural Assemblies. <i>Journal of Biological Chemistry</i> , 2015, 290, 3875-3892.	3.4	105
26	The intellectual disability protein RAB39B selectively regulates GluA2 trafficking to determine synaptic AMPAR composition. <i>Nature Communications</i> , 2015, 6, 6504.	12.8	93
27	Catching Functional Modes and Structural Communication in Dbl Family Rho Guanine Nucleotide Exchange Factors. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 1878-1893.	5.4	24
28	Comparison of the isomerization mechanisms of human melanopsin and invertebrate and vertebrate rhodopsins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1714-1719.	7.1	59
29	Multiscale quantum chemical approaches to QSAR modeling and drug design. <i>Drug Discovery Today</i> , 2014, 19, 1921-1927.	6.4	21
30	Quaternary Structure Predictions and Structural Communication Features of GPCR Dimers. <i>Progress in Molecular Biology and Translational Science</i> , 2013, 117, 105-142.	1.7	14
31	Network Analysis to Uncover the Structural Communication in GPCRs. <i>Methods in Cell Biology</i> , 2013, 117, 43-61.	1.1	19
32	The catalytic site structural gate of adenosine deaminase allosterically modulates ligand binding to adenosine receptors. <i>FASEB Journal</i> , 2013, 27, 1048-1061.	0.5	35
33	A Mixed Protein Structure Network and Elastic Network Model Approach to Predict the Structural Communication in Biomolecular Systems: The PDZ2 Domain from Tyrosine Phosphatase 1E As a Case Study. <i>Journal of Chemical Theory and Computation</i> , 2013, 9, 2504-2518.	5.3	52
34	Network and Atomistic Simulations Unveil the Structural Determinants of Mutations Linked to Retinal Diseases. <i>PLoS Computational Biology</i> , 2013, 9, e1003207.	3.2	31
35	Light on the structural communication in Ras GTPases. <i>Journal of Biomolecular Structure and Dynamics</i> , 2013, 31, 142-157.	3.5	19
36	Nucleotide Binding Affects Intrinsic Dynamics and Structural Communication in Ras GTPases. <i>Current Pharmaceutical Design</i> , 2013, 19, 4214-4225.	1.9	12

#	ARTICLE	IF	CITATIONS
37	The KDEL receptor couples to G $\alpha$ 11 to activate Src kinases and regulate transport through the Golgi. EMBO Journal, 2012, 31, 2869-2881.	7.8	105
38	Modeling the Structural Communication in Supramolecular Complexes Involving GPCRs. Methods in Molecular Biology, 2012, 914, 319-336.	0.9	4
39	Dimerization and ligand binding affect the structure network of A2A adenosine receptor. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 1256-1266.	2.6	59
40	Update 1 of: Computational Modeling Approaches to Structure-Function Analysis of G Protein-Coupled Receptors. Chemical Reviews, 2011, 111, PR438-PR535.	47.7	71
41	Conserved amino acids participate in the structure networks deputed to intramolecular communication in the lutropin receptor. Cellular and Molecular Life Sciences, 2011, 68, 1227-1239.	5.4	54
42	Light on the structure of thromboxane A2 receptor heterodimers. Cellular and Molecular Life Sciences, 2011, 68, 3109-3120.	5.4	23
43	Wordom: A user-friendly program for the analysis of molecular structures, trajectories, and free energy surfaces. Journal of Computational Chemistry, 2011, 32, 1183-1194.	3.3	232
44	The Extreme C-Terminal Region of G $\alpha$ s Differentially Couples to the Luteinizing Hormone and $\beta$ 2-Adrenergic Receptors. Molecular Endocrinology, 2011, 25, 1416-1430.	3.7	9
45	Nucleotide Binding Switches the Information Flow in Ras GTPases. PLoS Computational Biology, 2011, 7, e1001098.	3.2	39
46	Superactive mutants of thromboxane prostanoid receptor: functional and computational analysis of an active form alternative to constitutively active mutants. Cellular and Molecular Life Sciences, 2010, 67, 2979-2989.	5.4	14
47	Deciphering the Deformation Modes Associated with Function Retention and Specialization in Members of the Ras Superfamily. Structure, 2010, 18, 402-414.	3.3	46
48	Computational quantum chemistry and adaptive ligand modeling in mechanistic QSAR. Drug Discovery Today, 2010, 15, 859-866.	6.4	25
49	Structure-activity relationships in 1,4-benzodioxan-related compounds. 10. Novel $\beta$ 1-adrenoreceptor antagonists related to openphendioxan: Synthesis, biological evaluation, and $\beta$ 1d computational study. Bioorganic and Medicinal Chemistry, 2010, 18, 7065-7077.	3.0	12
50	Structural insights into retinitis pigmentosa from unfolding simulations of rhodopsin mutants. FASEB Journal, 2010, 24, 3196-3209.	0.5	39
51	The luteinizing hormone receptor: Insights into structure-function relationships and hormone-receptor-mediated changes in gene expression in ovarian cancer cells. Molecular and Cellular Endocrinology, 2010, 329, 47-55.	3.2	32
52	Computational Screening of Rhodopsin Mutations Associated with Retinitis Pigmentosa. Journal of Chemical Theory and Computation, 2009, 5, 2472-2485.	5.3	12
53	Network-level analysis of light adaptation in rod cells under normal and altered conditions. Molecular BioSystems, 2009, 5, 1232.	2.9	45
54	Adenosine A <sub>2A</sub> Receptor-Antagonist/Dopamine D <sub>2</sub> Receptor-Agonist Bivalent Ligands as Pharmacological Tools to Detect A <sub>2A</sub> -D <sub>2</sub> Receptor Heteromers. Journal of Medicinal Chemistry, 2009, 52, 5590-5602.	6.4	129

#	ARTICLE	IF	CITATIONS
55	Computational Modeling of Intramolecular and Intermolecular Communication in GPCRs. <i>Current Protein and Peptide Science</i> , 2009, 10, 173-185.	1.4	16
56	Ligand-Receptor Communication and Drug Design. <i>Current Protein and Peptide Science</i> , 2009, 10, 186-193.	1.4	7
57	Dark and photoactivated rhodopsin share common binding modes to transducin. <i>FEBS Letters</i> , 2008, 582, 991-996.	2.8	13
58	Homodimerization of Neurotensin 1 Receptor Involves Helices 1, 2, and 4: Insights from Quaternary Structure Predictions and Dimerization Free Energy Estimations. <i>Journal of Chemical Information and Modeling</i> , 2008, 48, 1669-1678.	5.4	31
59	Quaternary structure predictions and estimation of mutational effects on the free energy of dimerization of the OMPLA protein. <i>Journal of Structural Biology</i> , 2008, 163, 155-162.	2.8	8
60	Target Flexibility: An Emerging Consideration in Drug Discovery and Design. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6237-6255.	6.4	280
61	Mechanisms of Inter- and Intramolecular Communication in GPCRs and G Proteins. <i>Journal of the American Chemical Society</i> , 2008, 130, 4310-4325.	13.7	37
62	An Intracellular Loop (IL2) Residue Confers Different Basal Constitutive Activities to the Human Lutropin Receptor and Human Thyrotropin Receptor through Structural Communication between IL2 and Helix 6, via Helix 3. <i>Endocrinology</i> , 2008, 149, 1705-1717.	2.8	29
63	Contributions of Intracellular Loops 2 and 3 of the Lutropin Receptor in Gs Coupling. <i>Molecular Endocrinology</i> , 2008, 22, 126-138.	3.7	26
64	Intrinsic Differences in the Response of the Human Lutropin Receptor Versus the Human Follitropin Receptor to Activating Mutations. <i>Journal of Biological Chemistry</i> , 2007, 282, 25527-25539.	3.4	44
65	Dimerization of the lutropin receptor: Insights from computational modeling. <i>Molecular and Cellular Endocrinology</i> , 2007, 260-262, 59-64.	3.2	33
66	A functional transmembrane complex: The luteinizing hormone receptor with bound ligand and G protein. <i>Molecular and Cellular Endocrinology</i> , 2007, 260-262, 126-136.	3.2	63
67	Monomeric dark rhodopsin holds the molecular determinants for transducin recognition: Insights from computational analysis. <i>FEBS Letters</i> , 2007, 581, 944-948.	2.8	21
68	In Silico Screening of Mutational Effects on Transmembrane Helix Dimerization: Insights from Rigid-Body Docking and Molecular Dynamics Simulations. <i>Journal of Physical Chemistry B</i> , 2007, 111, 9114-9124.	2.6	20
69	In silico screening of mutational effects on enzyme-protein inhibitor affinity: a docking-based approach. <i>BMC Structural Biology</i> , 2007, 7, 37.	2.3	17
70	Sequential Unfolding of Individual Helices of Bacteriorhodopsin Observed in Molecular Dynamics Simulations of Extraction from the Purple Membrane. <i>Biophysical Journal</i> , 2006, 91, 3276-3284.	0.5	13
71	Prediction of MEF2A-DNA interface by rigid body docking: A tool for fast estimation of protein mutational effects on DNA binding. <i>Journal of Structural Biology</i> , 2006, 153, 278-283.	2.8	28
72	Inactive and active states and supramolecular organization of GPCRs: insights from computational modeling. <i>Journal of Computer-Aided Molecular Design</i> , 2006, 20, 449-461.	2.9	26

#	ARTICLE	IF	CITATIONS
73	Quaternary structure predictions of transmembrane proteins starting from the monomer: a docking-based approach. BMC Bioinformatics, 2006, 7, 340.	2.6	45
74	Structure-Function Relationships of the Luteinizing Hormone Receptor. Annals of the New York Academy of Sciences, 2005, 1061, 41-54.	3.8	26
75	Computational Modeling Approaches to Structure-Function Analysis of G Protein-Coupled Receptors. ChemInform, 2005, 36, no.	0.0	0
76	Different Structural Requirements for the Constitutive and the Agonist-induced Activities of the $\beta_2$ -Adrenergic Receptor. Journal of Biological Chemistry, 2005, 280, 23464-23474.	3.4	13
77	The Formation of a Salt Bridge Between Helices 3 and 6 Is Responsible for the Constitutive Activity and Lack of Hormone Responsiveness of the Naturally Occurring L457R Mutation of the Human Lutropin Receptor. Journal of Biological Chemistry, 2005, 280, 26169-26176.	3.4	52
78	Rhodopsin Activation Follows Precoupling with Transducin: Inferences from Computational Analysis,. Biochemistry, 2005, 44, 14695-14700.	2.5	40
79	The DRY Motif as a Molecular Switch of the Human Oxytocin Receptor. Biochemistry, 2005, 44, 9990-10008.	2.5	39
80	Probing Fragment Complementation by Rigid-Body Docking: In Silico Reconstitution of Calbindin D9k. Journal of Chemical Information and Modeling, 2005, 45, 1429-1438.	5.4	15
81	Computational Modeling Approaches to Structure-Function Analysis of G Protein-Coupled Receptors. Chemical Reviews, 2005, 105, 3297-3351.	47.7	158
82	Insight into Mutation-Induced Activation of the Luteinizing Hormone Receptor: Molecular Simulations Predict the Functional Behavior of Engineered Mutants at M398. Molecular Endocrinology, 2004, 18, 1499-1508.	3.7	35
83	Structural determinants involved in the activation and regulation of G protein-coupled receptors: lessons from the $\alpha_1$ -adrenergic receptor subtypes. Biology of the Cell, 2004, 96, 327-333.	2.0	13
84	Structural features of the inactive and active states of the melanin-concentrating hormone receptors: Insights from molecular simulations. Proteins: Structure, Function and Bioinformatics, 2004, 56, 430-448.	2.6	22
85	Synthesis, Screening, and Molecular Modeling of New Potent and Selective Antagonists at the $\beta_1$ -Adrenergic Receptor. Journal of Medicinal Chemistry, 2004, 47, 1900-1918.	6.4	52
86	Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism and Related Disorders, 2004, 10, 265-271.	2.2	132
87	Structural determinants involved in the activation and regulation of G protein-coupled receptors: lessons from the $\alpha_1$ -adrenergic receptor subtypes. Biology of the Cell, 2004, 96, 327-333.	2.0	11
88	Molecular Dynamics Simulations of the Ligand-Induced Chemical Information Transfer in the 5-HT1A Receptor.. ChemInform, 2003, 34, no.	0.0	0
89	Molecular Dynamics Simulations of the Ligand-Induced Chemical Information Transfer in the 5-HT1A Receptor. Journal of Chemical Information and Computer Sciences, 2003, 43, 1520-1531.	2.8	29
90	Adenosine A2A-Dopamine D2 Receptor-Receptor Heteromerization. Journal of Biological Chemistry, 2003, 278, 46741-46749.	3.4	401

#	ARTICLE	IF	CITATIONS
91	Constitutively Active G Protein-Coupled Receptor Mutants: Implications on Receptor Function and Drug Action. <i>Assay and Drug Development Technologies</i> , 2003, 1, 311-316.	1.2	15
92	Mutagenesis and Modelling of the $\hat{1}\pm 1b$ -Adrenergic Receptor Highlight the Role of the Helix 3/Helix 6 Interface in Receptor Activation. <i>Molecular Pharmacology</i> , 2002, 61, 1025-1032.	2.3	114
93	A Model for Constitutive Lutropin Receptor Activation Based on Molecular Simulation and Engineered Mutations in Transmembrane Helices 6 and 7. <i>Journal of Biological Chemistry</i> , 2002, 277, 32202-32213.	3.4	67
94	The Lutropin/Choriogonadotropin Receptor, A 2002 Perspective. <i>Endocrine Reviews</i> , 2002, 23, 141-174.	20.1	671
95	THE $\hat{1}\pm 1b$ -ADRENERGIC RECEPTOR SUBTYPE: MOLECULAR PROPERTIES AND PHYSIOLOGICAL IMPLICATIONS. <i>Journal of Receptor and Signal Transduction Research</i> , 2002, 22, 1-16.	2.5	11
96	Structural Aspects of Luteinizing Hormone Receptor: Information from Molecular Modeling and Mutagenesis. <i>Endocrine</i> , 2002, 18, 285-294.	2.2	15
97	The Lutropin/Choriogonadotropin Receptor, A 2002 Perspective. , 2002, 23, 141-174.		167
98	Understanding the Mutation-Induced Activation of the Lutropin Receptor from Computer Simulation. , 2002, , 29-38.		0
99	Phenylpiperazinylalkylamino Substituted Pyridazinones as Potent $\hat{1}\pm 1$ Adrenoceptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 2403-2410.	6.4	28
100	Lutropin Receptor Function: Insights from Natural, Engineered, and Computer-Simulated Mutations. <i>IUBMB Life</i> , 2001, 51, 149-155.	3.4	21
101	Mutational and Computational Analysis of the $\hat{1}\pm 1b$ -Adrenergic Receptor. <i>Journal of Biological Chemistry</i> , 2001, 276, 46485-46494.	3.4	73
102	Pleiotropic Effects of Substitutions of a Highly Conserved Leucine in Transmembrane Helix III of the Human Lutropin/Choriogonadotropin Receptor with Respect to Constitutive Activation and Hormone Responsiveness. <i>Molecular Endocrinology</i> , 2001, 15, 972-984.	3.7	38
103	Pleiotropic Effects of Substitutions of a Highly Conserved Leucine in Transmembrane Helix III of the Human Lutropin/Choriogonadotropin Receptor with Respect to Constitutive Activation and Hormone Responsiveness. <i>Molecular Endocrinology</i> , 2001, 15, 972-984.	3.7	15
104	The $\hat{1}\pm 1a$ and $\hat{1}\pm 1b$ -adrenergic receptor subtypes: molecular mechanisms of receptor activation and of drug action. <i>Pharmacochemistry Library</i> , 2000, 31, 173-179.	0.1	0
105	Molecular basis of ligand binding and receptor activation in the oxytocin and vasopressin receptor family. <i>Experimental Physiology</i> , 2000, 85, 59s-66s.	2.0	30
106	The ad hoc supermolecule approach to receptor ligand design. <i>Computational and Theoretical Chemistry</i> , 2000, 503, 1-16.	1.5	7
107	The $\hat{1}\pm 1a$ and $\hat{1}\pm 1b$ -adrenergic receptor subtypes: molecular mechanisms of receptor activation and of drug action. <i>Pharmaceutica Acta Helveticae</i> , 2000, 74, 173-179.	1.2	14
108	Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4. <i>Journal of Computer-Aided Molecular Design</i> , 2000, 14, 93-116.	2.9	59



#	ARTICLE	IF	CITATIONS
109	Gonadotropin-Independent Precocious Puberty Due to Luteinizing Hormone Receptor Mutations in Brazilian Boys: A Novel Constitutively Activating Mutation in the First Transmembrane Helix1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4799-4805.	3.6	49
110	Theoretical study on mutation-induced activation of the luteinizing hormone receptor 1 1Edited by F. E. Cohen. Journal of Molecular Biology, 2000, 296, 1333-1351.	4.2	45
111	Gonadotropin-Independent Precocious Puberty Due to Luteinizing Hormone Receptor Mutations in Brazilian Boys: A Novel Constitutively Activating Mutation in the First Transmembrane Helix. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4799-4805.	3.6	50
112	Mutational analysis of the highly conserved arginine within the Glu/Asp-Arg-Tyr motif of the alpha(1b)-adrenergic receptor: effects on receptor isomerization and activation. Molecular Pharmacology, 2000, 57, 219-31.	2.3	93
113	Inverse Agonism and Neutral Antagonism at $\hat{1}\pm<sub>1a</sub></math>- and \hat{1}\pm<sub>1b</sub></math>-Adrenergic Receptor Subtypes. Molecular Pharmacology, 1999, 56, 858-866.$	2.3	86
114	Activation Mechanism of Human Oxytocin Receptor: A Combined Study of Experimental and Computer-Simulated Mutagenesis. Molecular Pharmacology, 1999, 56, 214-225.	2.3	88
115	Theoretical study on receptor-G protein recognition: New insights into the mechanism of the $\hat{1}b<sub>1</sub></math>-adrenergic receptor activation. International Journal of Quantum Chemistry, 1999, 73, 71-83.$	2.0	19
116	Theoretical study of the electrostatically driven step of receptor-G protein recognition. , 1999, 37, 145-156.		31
117	Structure-Function Relationships of the $\alpha<sub>1b</sub></math>-Adrenergic Receptor. European Urology, 1999, 36, 11-16.$	1.9	7
118	Theoretical study on receptorâ€G protein recognition: New insights into the mechanism of the $\hat{1}\pm 1b<sub>1</sub></math>-adrenergic receptor activation. International Journal of Quantum Chemistry, 1999, 73, 71-83.$	2.0	1
119	Theoretical study of the electrostatically driven step of receptor-G protein recognition. Proteins: Structure, Function and Bioinformatics, 1999, 37, 145-56.	2.6	9
120	Molecular mechanisms involved in the activation and regulation of the $\hat{1}\pm 1<sub>1</sub></math>-adrenergic receptor subtypes. Il Farmaco, 1998, 53, 273-277.$	0.9	9
121	Isoxazolo-[3,4- d ]-pyridazin-7-(6 H )-ones and their Corresponding 4,5-Disubstituted-3-(2 H ) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Modeling, and Binding Studies. Bioorganic and Medicinal Chemistry, 1998, 6, 925-935.	3.0	33
122	Hydrophobicity of Residue351of the G Protein Gi1 $\hat{1}\pm$ Determines the Extent of Activation by the $\hat{1}\pm 2A<sub>1</sub></math>-Adrenoceptorâ€€. Biochemistry, 1998, 37, 11555-11562.$	2.5	87
123	Computer Modeling of Size and Shape Descriptors of $\hat{1}\pm 1<sub>1</sub></math>-Adrenergic Receptor Antagonists and Quantitative Structureâ€Affinity/Selectivity Relationships. Methods, 1998, 14, 239-254.$	3.8	14
124	Ab InitioModeling and Molecular Dynamics Simulation of the $\hat{1}\pm 1b<sub>1</sub></math>-Adrenergic Receptor Activation. Methods, 1998, 14, 302-317.$	3.8	38
125	Identification of a Constitutively Active Mutant of the Human Oxytocin Receptor. Advances in Experimental Medicine and Biology, 1998, 449, 367-369.	1.6	3
126	The activation process of the $\hat{A}1B<sub>1</sub></math>-adrenergic receptor: Potential role of protonation and hydrophobicity of a highly conserved aspartate. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 808-813.$	7.1	207



#	ARTICLE	IF	CITATIONS
127	Constitutively active $\beta$ 1B-adrenergic receptor mutants: Potential mechanisms underlying receptor activation. Pharmacochimistry Library, 1997, 28, 421-431.	0.1	0
128	Conformational analysis and theoretical quantitative size and shape-affinity relationships of N4-protonated N1-arylpiperazine 5-HT1A serotonergic ligands. Computational and Theoretical Chemistry, 1997, 397, 129-145.	1.5	11
129	$\beta$ 1-Adrenoceptor subtype selectivity: Molecular modelling and theoretical quantitative structure-activity relationships. Bioorganic and Medicinal Chemistry, 1997, 5, 809-816.	3.0	27
130	Theoretical investigation of IL-6 multiprotein receptor assembly. , 1997, 29, 528-548.		9
131	Amino acids of the $\beta$ 1B-adrenergic receptor involved in agonist binding: differences in docking catecholamines to receptor subtypes. FEBS Letters, 1996, 399, 9-13.	2.8	70
132	Molecular mechanisms underlying the activation and regulation of the $\beta$ 1B-adrenergic receptor. Biochemical Society Transactions, 1996, 24, 959-963.	3.4	2
133	MOLECULAR MECHANISMS UNDERLYING THE ACTIVATION AND REGULATION OF THE $\beta$ 1-ADRENERGIC RECEPTOR. Biochemical Society Transactions, 1996, 24, 517S-517S.	3.4	0
134	Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation.. EMBO Journal, 1996, 15, 3566-3578.	7.8	338
135	Computational simulations of stem-cell factor/c-Kit receptor interaction. , 1996, 26, 42-54.		2
136	Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. EMBO Journal, 1996, 15, 3566-78.	7.8	95
137	Molecular dynamics simulations of m3-muscarinic receptor activation and QSAR analysis. Bioorganic and Medicinal Chemistry, 1995, 3, 1465-1477.	3.0	20
138	Theoretical quantitative structure-activity relationship analysis of congeneric and non-congeneric $\beta$ 1-adrenoceptor antagonists: a chemometric study. Computational and Theoretical Chemistry, 1995, 331, 79-93.	1.5	26
139	Quantitative structure-affinity/selectivity relationship analysis on three-dimensional models of the complexes between the ETA and ETB receptors and C-terminal endothelin hexapeptide antagonists. Computational and Theoretical Chemistry, 1995, 333, 243-248.	1.5	5
140	Comparative molecular dynamics study of the seven-helix bundle arrangement of G-protein coupled receptors. Computational and Theoretical Chemistry, 1995, 333, 49-69.	1.5	18
141	Prototropic molecular forms and theoretical descriptors in QSAR analysis. Computational and Theoretical Chemistry, 1995, 333, 1-17.	1.5	11
142	Computer simulations of signal transduction mechanism in $\beta$ 1B-adrenergic and m3-muscarinic receptors. Protein Engineering, Design and Selection, 1995, 8, 557-564.	2.1	20
143	Theoretical quantitative structure-activity relationship analysis on three dimensional models of ligand-m1 muscarinic receptor complexes. Bioorganic and Medicinal Chemistry, 1994, 2, 195-211.	3.0	23
144	The heuristic-direct approach to theoretical quantitative structure-activity relationship analysis of $\beta$ 1-adrenoceptor ligands. Computational and Theoretical Chemistry, 1994, 314, 265-276.	1.5	13

#	ARTICLE	IF	CITATIONS
145	Theoretical quantitative size and shape activity and selectivity analyses of 5-HT1A serotonin and $\alpha$ 1-adrenergic receptor ligands. Computational and Theoretical Chemistry, 1994, 305, 101-110.	1.5	16
146	Enantiomeric resolution of sulfoxides on a DACH-DNB chiral stationary phase: A quantitative structure-enantioselective retention relationship (QSERR) study. Chirality, 1993, 5, 527-537.	2.6	44
147	Theoretical quantitative structure-activity analysis and pharmacophore modelling of selective non-congeneric $\alpha$ 1a-adrenergic antagonists. Computational and Theoretical Chemistry, 1993, 280, 283-290.	1.5	14
148	The heuristic-direct approach to quantitative structure-activity relationship analysis. Computational and Theoretical Chemistry, 1993, 285, 147-153.	1.5	18
149	Theoretical quantitative structure-activity analysis of quinuclidine-based muscarinic cholinergic receptor ligands. Computational and Theoretical Chemistry, 1993, 283, 63-71.	1.5	11
150	Molecular modelling and quantitative structure- activity relationship analysis using theoretical descriptors of 1,4-benzodioxan (WB-4101) related compounds $\alpha$ 1-adrenergic antagonists. Computational and Theoretical Chemistry, 1992, 276, 327-340.	1.5	20
151	Conformational analysis, molecular modeling and quantitative structure-activity relationship studies of 2,4-diamino-6,7-dimethoxy-2-substituted quinazoline $\alpha$ 1-adrenergic antagonists. Computational and Theoretical Chemistry, 1991, 251, 307-318.	1.5	20
152	Chapter 8. Uncovering GPCR and G Protein Function by Protein Structure Network Analysis. Chemical Biology, 0, , 198-220.	0.2	1